Literature DB >> 11220411

Problem pathogens (Pseudomonas aeruginosa and Acinetobacter).

J Chastre1, J L Trouillet.   

Abstract

A number of factors have been suspected of or identified as increasing the risk for pneumonia or colonization of the lower respiratory tract by Pseudomonas and/or Acinetobacter spp. in the intensive care unit (ICU), including advanced age, chronic lung disease, immunosuppression, surgery, use of antimicrobial agents, presence of such invasive devices as endotracheal and gastric tubes, and type of respiratory equipment. However, there is little doubt that of all these factors, extended ICU care because of severe underlying disease, prolonged respiratory therapy with mechanical ventilation, and prior antimicrobial therapy are the most important. Because the only factor amenable to prevention in this setting is antimicrobial therapy, avoiding unnecessary antibiotics should be a high priority in the management of such patients. Crude mortality rates of 30% to 75% have been reported for nosocomial pneumonia caused by Pseudomonas and/or Acinetobacter spp., with the highest rates reported in ventilator-dependent patients. It is therefore clear that the prognosis associated with this type of infection is considerably worse than that associated with infection caused by other gram-negative or gram-positive bacteria. Because bactericidal synergy against Pseudomonas and Acinetobacter spp. has been shown when carbenicillin and an aminoglycoside are combined, the use of an effective beta-lactam (piperacillin, ticarcillin, ceftazidime, or imipenem) and aminoglycoside combination remains the preferred therapeutic approach when possible. Future research efforts should also aim to improve our ability to diagnose and exclude infection in the ICU setting to avoid administering unnecessary antibiotics to patients without true pulmonary infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11220411     DOI: 10.1053/srin.2000.20944

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  26 in total

1.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Role of Interleukin-17 in defense against pseudomonas aeruginosa infection in lungs.

Authors:  Xilin Xu; Bing Shao; Ran Wang; Sijing Zhou; Zhongzhi Tang; Weihua Lu; Shengdao Xiong
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.

Authors:  Yoshimitsu Nakano; Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Burns       Date:  2010-04-14       Impact factor: 2.744

5.  Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats.

Authors:  Sandrine Marchand; Claire Dahyot; Isabelle Lamarche; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea.

Authors:  Byung-Chan Jeon; Seok Hoon Jeong; Il Kwon Bae; Su Bong Kwon; Kyungwon Lee; Dongeun Young; Jung Hun Lee; Jae Seok Song; Sang Hee Lee
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

8.  Requirement of the Pseudomonas aeruginosa CbrA sensor kinase for full virulence in a murine acute lung infection model.

Authors:  Amy T Y Yeung; Laure Janot; Olga M Pena; Anke Neidig; Irena Kukavica-Ibrulj; Ashley Hilchie; Roger C Levesque; Joerg Overhage; Robert E W Hancock
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

9.  Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India.

Authors:  Viren A Javiya; Somsuvra B Ghatak; Kamlesh R Patel; Jagruti A Patel
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

10.  Colistin and polymyxin B: a re-emergence.

Authors:  Sachin Gupta; Deepak Govil; Prem N Kakar; Om Prakash; Deep Arora; Shibani Das; Pradeep Govil; Ashima Malhotra
Journal:  Indian J Crit Care Med       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.